Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment

Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in... Purpose of reviewPosttransplant lymphoproliferative disorder (PTLD) is a serious complication following transplantation from an allogeneic donor. Epstein-Barr Virus (EBV) is involved in a substantial number of cases. In this review, we aim to summarize recent knowledge on pathogenesis, classification and treatment of EBV+ PTLD.Recent findingsNew insights in the complex oncogenic properties of EBV antigens noncoding Ribonucleic acids (RNAs), especially EBV MicroRNA (miRNAs), have increased our knowledge of the pathogenesis of EBV+ PTLD. In addition the potential influence of EBV on the tumor microenvironment is becoming clearer, paving the way for new types of immunotherapy. Currently PTLD is classified according to the World Health Organization classification together with other lymphoproliferative disorders, based on the specific immunosuppression. However, a new framework integrating all types of lymphoproliferative disorders in all different settings of immune deficiency and dysregulation is needed. Although treatment of EBV+ and EBV- PTLD was largely similar in the past, EBV-directed therapies are currently increasingly used.SummaryThe use of EBV-directed therapies and new agents, based on better understanding of pathogenesis and classification of PTLD, will change the treatment landscape of EBV+ PTLD in the next era. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Oncology Wolters Kluwer Health

Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment

Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/epstein-barr-virus-associated-posttransplant-lymphoproliferative-23hCJoI0Up

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1040-8746
eISSN
1531-703X
DOI
10.1097/cco.0000000000000885
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewPosttransplant lymphoproliferative disorder (PTLD) is a serious complication following transplantation from an allogeneic donor. Epstein-Barr Virus (EBV) is involved in a substantial number of cases. In this review, we aim to summarize recent knowledge on pathogenesis, classification and treatment of EBV+ PTLD.Recent findingsNew insights in the complex oncogenic properties of EBV antigens noncoding Ribonucleic acids (RNAs), especially EBV MicroRNA (miRNAs), have increased our knowledge of the pathogenesis of EBV+ PTLD. In addition the potential influence of EBV on the tumor microenvironment is becoming clearer, paving the way for new types of immunotherapy. Currently PTLD is classified according to the World Health Organization classification together with other lymphoproliferative disorders, based on the specific immunosuppression. However, a new framework integrating all types of lymphoproliferative disorders in all different settings of immune deficiency and dysregulation is needed. Although treatment of EBV+ and EBV- PTLD was largely similar in the past, EBV-directed therapies are currently increasingly used.SummaryThe use of EBV-directed therapies and new agents, based on better understanding of pathogenesis and classification of PTLD, will change the treatment landscape of EBV+ PTLD in the next era.

Journal

Current Opinion in Oncology – Wolters Kluwer Health

Published: Sep 27, 2022

References

  • Molecular basis of Epstein–Barr Virus latency establishment and lytic reactivation
  • Epstein-Barr virus: current questions and challenges
  • The role of lytic infection for lymphomagenesis of human (-herpesviruses
  • A review on human carcinogens--Part B: biological agents
  • Immune escape by noncoding RNAs of the Epstein Barr virus
  • Opportunities to target the life cycle of Epstein-Barr Virus (EBV) in EBV-associated lymphoproliferative disorders
  • Oncogenic properties of the EBV ZEBRA protein
  • The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination
  • Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells
  • Epstein-Barr virus-associated posttransplant lymphoproliferative disorders after hematopoietic stem cell transplantation: pathogenesis, risk factors and clinical outcomes
  • EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2
  • Targeted therapies for Epstein-Barr virus-associated lymphomas
  • Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) proteins regulate EBNA2 binding to distinct RBPJ genomic sites
  • Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder
  • The role of EBV-encoded LMP1 in the NPC tumor microenvironment: from function to therapy
  • Epstein-Barr Virus latent membrane protein 1 regulates host B cell MicroRNA-155 and its target FOXO3a via PI3k p110α activation
  • The immune response to Epstein Barr Virus and implications for posttransplant lymphoproliferative disorder
  • Comparative analysis of posttransplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment
  • The prognostic value of tumour-associated macrophages in Non-Hodgkin's lymphoma: a systematic review and meta-analysis
  • EB virus-induced ATR activation accelerates nasopharyngeal carcinoma growth via M2-type macrophages polarization
  • Co-infection of Cytomegalovirus and Epstein-Barr virus diminishes the frequency of CD56dimNKG2A+KIR− NK cells and contributes to suboptimal control of EBV in immunosuppressed children with oost-transplant lymphoproliferative disorder
  • Posttransplant lymphoproliferative disorders
  • The 2016 revision of the World Health Organization classification of lymphoid neoplasms
  • Immunodeficiency and dysregulation: report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology
  • Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?
  • B-cell and classical Hodgkin lymphomas associated with immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2
  • Clinicopathologic characteristics, treatment, and outcomes of posttransplant lymphoproliferative Disorders: a single-institution experience using 2017 WHO diagnostic criteria
  • Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors
  • Posttransplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
  • A population-based study of 135 lymphomas after solid organ transplantation; the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival
  • Viral hit and run-oncogenesis: genetic and epigenetic scenarios
  • Spontaneous loss of viral episomes accompanying Epstein-Barr virus reactivation in a Burkitt's lymphoma cell line
  • Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders
  • EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features
  • Mutational landscape of B-cell posttransplant lymphoproliferative disorders
  • PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
  • Epstein-Barr virus-associated malignancies and immune escape: the role of the tumor microenvironment and tumor cell evasion strategies
  • Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature
  • EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features
  • Cancer and mTOR inhibitors in transplant recipients
  • Factors associated with posttransplant active Epstein-Barr Virus infection and lymphoproliferative disease in hematopoietic stem cell transplant recipients ; a systematic review and meta-analysis
  • Posttransplantation lymphoproliferative disorders in adults
  • Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder
  • Reduction of immunosuppression for posttransplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes
  • Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience
  • Response to rituximab induction is a predictive marker in B-cell posttransplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial
  • EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT
  • Impact of the posttransplant lymphoproliferative disorder subtype on survival
  • EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target
  • Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
  • Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
  • A multicenter UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent
  • Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
  • Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication
  • Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
  • Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
  • Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
  • EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity
  • A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
  • Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr Virus lytic cycle through phosphoinositide 3-kinase signaling and Ikaros expression
  • Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy
  • Succesful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to posttransplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells
  • Inhibition of BTK and ITK with ibrutinib Is effective in the prevention of chronic graft-versus-host disease in mice
  • PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas
  • Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival
  • Occurrence and prognostic relevance of CD30 expression in posttransplant lymphoproliferative disorders
  • CD30 expression and survival in posttransplant lymphoproliferative disorders
  • A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
  • Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in posttransplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome
  • Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation
  • Classical Hodgkin lymphoma-like posttransplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report
  • Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient
  • Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
  • PD-1 Blockade aggravates Epstein–Barr Virus+ posttransplant lymphoproliferative disorder in humanized mice resulting in central nervous system involvement and CD4+ T cell dysregulations
  • Co-stimulatory molecules during immune control of Epstein Barr Virus infection
  • Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
  • CAR-T therapy in solid transplant recipients with posttransplant lymphoproliferative disease: case report and literature review
  • Malignant lymphomas in transplantation patients